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ORIGINAL ARTICLE VIROLOGYHuman bocavirus infection as a cause of severe acute respiratory tract
infection in childrenF. M. Moesker1, J. J. A. van Kampen1, A. A. van der Eijk1, A. M. C. van Rossum2, M. de Hoog3, M. Schutten1, S. L. Smits1,
R. Bodewes1, A. D. M. E. Osterhaus1,4 and P. L. A. Fraaij1,2
1) Department of Viroscience, Erasmus MC, Rotterdam, 2) Department of Paediatrics, 3) Department of Paediatrics, Paediatric Intensive Care Unit,
Erasmus MC-Sophia, Rotterdam, The Netherlands and 4) Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine,
Hannover, GermanyAbstractIn 2005 human bocavirus (HBoV) was discovered in respiratory tract samples of children. The role of HBoV as the single causative agent for
respiratory tract infections remains unclear. Detection of HBoV in children with respiratory disease is frequently in combination with other
viruses or bacteria. We set up an algorithm to study whether HBoV alone can cause severe acute respiratory tract infection (SARI) in
children. The algorithm was developed to exclude cases with no other likely cause than HBoV for the need for admission to the
paediatric intensive care unit (PICU) with SARI. We searched for other viruses by next-generation sequencing (NGS) in these cases and
studied their HBoV viral loads. To benchmark our algorithm, the same was applied to respiratory syncytial virus (RSV)-positive patients.
From our total group of 990 patients who tested positive for a respiratory virus by means of RT-PCR, HBoV and RSV were detected in
178 and 366 children admitted to our hospital. Forty-nine HBoV-positive patients and 72 RSV-positive patients were admitted to the
PICU. We found seven single HBoV-infected cases with SARI admitted to PICU (7/49, 14%). They had no other detectable virus by NGS.
They had much higher HBoV loads than other patients positive for HBoV. We identiﬁed 14 RSV-infected SARI patients with a single RSV
infection (14/72, 19%). We conclude that our study provides strong support that HBoV can cause SARI in children in the absence of
viral and bacterial co-infections.
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E-mail: p.fraaij@erasmusmc.nlIntroductionIn the past decade, many unknown viruses have been identiﬁed
using novel molecular pathogen discovery techniques [1]. After
detection, it is not always clear if these newly discovered vi-
ruses are able to cause disease. For some viruses it remainsMicrobiol Infect 2015; 21: 964.e1–964.e8
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.014difﬁcult to rule out simultaneous infections in the patient with
other known or yet unknown pathogens. Human bocavirus
(HBoV) is a clear example of such a newly discovered virus.
Human bocavirus was discovered in 2005 in respiratory tract
samples from children suffering acute respiratory tract in-
fections [2]. Currently, four genotypes have been described
(HBoV1–4) [3]. Based on seroprevalence studies, HBoV-
speciﬁc antibodies in adults range from 64 to 95%, indicating
the high number of HBoV encounters [4]. HBoV infection in
children has been associated with respiratory tract infections
(HBoV1–2) and gastrointestinal disease (HBoV2–4) [3]. HBoV
infection results often in a mild self-limiting respiratory tract
infection and may even be asymptomatic [3,5]. Many childrenious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Baseline characteristics of selected human
bocavirus and respiratory syncytial virus RT-PCR-positive
patients admitted to the paediatric intensive care unit at the
















Female, n (%) 4 (57) 5 (29)
Male, n (%) 3 (43) 12 (71)
Reason for admission, n (%)
Respiratory failure 3 (43) 16 (94)
ECMO indication due to
respiratory failure
1 (14) —
Bronchiolitis/PSA 3 (43) —
ALTE with ARTI — 1 (6)
Clinical diagnosis at admittance, n (%)
URTI — 1 (6)
LRTI 1 (14) 1 (6)
BHR/PSA 4 (57) —
ARDS 1 (14) —
Severe atelectasis with ARTI 1 (14) —
Bronchiolitis — 15 (88)
CMI Moesker et al. A single human bocavirus infection can cause severe disease 964.e2shed HBoV in the respiratory tract for prolonged periods,
making interpretation of a positive test result in a patient
difﬁcult [6]. Nonetheless, a few case reports describe HBoV as
the cause of severe acute respiratory tract infection (SARI) in
children requiring intensive care. Although the role of other
pathogens was addressed, co-infections were not excluded
using a structured method [3,7–14]. Altogether, this has
resulted in the on-going debate of whether HBoV as the single
causative agent can cause disease.
To address this issue, we set up an algorithm to exclude
cases with no other likely cause than HBoV for the need for
intensive care. We searched for overlooked viruses by next-
generation sequencing (NGS) in these cases and studied their
HBoV viral loads. To benchmark this method, the same algo-
rithm was applied to patients with respiratory syncytial virus
(RSV) infection. As RSV is generally considered to be a well-
established paediatric pathogen that can cause SARI in chil-
dren [15–17].
Medical history, n (%)
None 3 (43) 6 (35)
Pulmonary disease 3 (43) 2 (12)
GSA <37 weeks — 2 (12)
GSA <37 weeks and pulmonary 1 (14) —Materials and methods
disease




Macrosome or dysmature — 2 (12)
Laboratory testing, median (min–max, IQR)
CRP (mg/L) 8 (1–36, 5–28) 8 (2–22, 4–11.5)
WBC count (×109/L) 13.6 (8.1–27,
9.3–20)
13.5 (8.7–33, 10.5–15)
Sputum obtained and start antibiotics, n (%)
 12 hours before sputum
obtained
1 (14) 3 (17)
> 12 hours after sputum obtained 4 (57) 4 (24)
Sputum not obtained, n (%) 2 (28) 10 (59)
Respiratory support, n (%)
Supplemental 1 (14) 7 (41)
Invasive 5 (72) 10 (59)
ECMO 1 (14) —
PICU admission duration (days)
median (min–max)
4 (2–7) 4 (2–29)
Survival, n (%) 7 (100) 17 (100)
Viral metagenomics, n (%)
HBoV as sole viral pathogen
detected
7 (100) —
RSV as sole viral pathogen
detected
— 14(82)a
Abbreviations: ALTE, acute life-threatening event; ARDS, acute respiratory distress
syndrome; ARTI, acute respiratory tract infection; BHR, bronchial hyperreactivity;
CRP, C-reactive protein; ECMO, extracorporeal membrane oxygenation; GSA,
gestational age; HBoV, human bocavirus; LRTI, lower respiratory tract infection;
PICU, paediatric intensive care unit; PSA, paediatric status asthmaticus; RSV,
respiratory syncytial virus; URTI, upper respiratory tract infection; WBC, white
blood cells.
aOne sample could not be processed, one tested negative for viruses, one tested
positive for rhinovirus.Patient and sample selection
We conducted a retrospective cohort study during 5 consec-
utive years from April 2007 through March 2012. We selected
paediatric patients (<18 years) admitted to the Paediatric
Intensive Care Unit (PICU) of Erasmus MC-Sophia, which is a
tertiary paediatric referral centre. This is the sole PICU for a
region with a general population of ~4 million and an annual
birth cohort of ~47 000 children [18].
We selected respiratory tract samples of these patients that
tested positive with real-time RT-PCRs for respiratory viral
diagnostics. We used the electronic laboratory information
management system of the Viroscience Department to obtain
all test results. Samples included nasal washings, sputum, throat
swabs and bronchoalveolar lavages, which were obtained dur-
ing routine clinical practice. We only used the ﬁrst available
sample of each patient. A viral pathogen was deﬁned if a cycle
threshold value (Ct-value) <40 was detected for adenoviruses,
coronaviruses (OC43, 229E and NL63), HBoV1–4, human
metapneumovirus, inﬂuenza A and B viruses, parainﬂuenza vi-
ruses 1–4, RSV and/or rhinoviruses [19]. The Ct-value repre-
sents the number of cycles required for the ﬂuorescent signal
to cross the threshold (exceeds background level) and is
inversely related to viral load.
Algorithm
All HBoV RT-PCR-positive cases, with or without co-infections,
were originally included. Next, four selection steps were
applied: ﬁrst, we selected all PICU-admitted patients, as theseClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inpatients are critically ill and key for testing our hypothesis.
Second, patients with a viral co-detection upon RT-PCR were
excluded. Third, selected clinical data were extracted from
electronic medical ﬁles of the patients. Only patients with SARI
as the reason for admission were included (see Table 1 and
Supplementary material, Table S1). Fourth, absence of bacterial
co-infections was considered likely if C-reactive protein (CRP)
levels were 40 mg/L upon admission and bacterial cultures
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 964.e1–964.e8
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cultures. We deﬁned a sputum culture negative if ten or fewer
bacteria per ocular ﬁeld were present in Gram staining, if no
respiratory pathogenic bacteria were cultured, and/or when
commensal bacterial growth was 2/4. Sputa containing fewer
than ten epithelial cells per ocular ﬁeld (10 × 10 magniﬁcation)
were considered quality sputa. Sputa containing ten or more
epithelial cells per ocular ﬁeld were only considered quality
sputa if the leucocyte-to-epithelial cell ratio was 10 and more
than six bacteria with the same morphology were present.
Absence of a sputum culture was not a reason for exclusion, as
sputum is not easily obtained from children. A reason for
exclusion was if other bacterial cultures tested positive, such as
a cerebrospinal ﬂuid cultures or blood cultures.
Lastly, selected samples were tested for Mycoplasma pneu-
moniae using RT-PCR and only negative samples were used for
NGS. Conﬁrmatory serology detecting antibodies against HBoV
or RSV was not performed, as serum samples were not
collected routinely from these patients.
Three investigators independently reviewed the previously
described selection steps and disagreement was resolved by
consensus (FM, JVK and PF).
Next-generation sequencing
After applying the algorithm, samples were analysed for the
presence of known and unknown viruses. We used a viral meta-
genomics procedure as previously described, which includes
random RNA and DNA ampliﬁcation in combination with NGS
(454 Life Sciences®, Branford, CT, USA) [20,21]. In brief, the
amplicons of random RNA and DNA ampliﬁcation were pooled
and puriﬁed, after which rapid library preparation, emulsion PCR
and NGS were performed. Iterative exhaustive assembly of se-
quences was applied according to our virus discovery pipeline
written in the python programming language (PYTHON 2.7). An
absoluteminimumof two readswas required for a distinct hit to be
reported. Hits positive for endogenous retroviruses or anellovi-
ruses were excluded from analysis. Presence of genome material
for bovine viruses was discarded because bovine reagents were
used. Sequences were deposited in GenBank and given accession
numbers (see Supplementary material; Supplementary data).
Phylogenetic analysis of HBoV
We performed phylogenetic analyses to study whether a spe-
ciﬁc HBoV subtype could be linked to a more virulent HBoV
infection resulting in PICU admission. We used the VP1/VP2
genes for sequence analysis, after which a phylogenetic tree was
reconstructed. Samples tested were HBoV RT-PCR-positive
selected cases for NGS and selected controls. Controls were
samples of patients with Ct-value <30, which is the minimum
requirement to sequence HBoV in this method. These controlClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectsamples were obtained from children whether or not they
were admitted to PICU, without SARI and with co-infections.
Two samples were obtained from children born in hospital
and admitted for more than 90 days and were called nosoco-
mially infected controls. All samples were ampliﬁed and
sequenced as described previously [22]. Phylogenetic analyses
were conducted with MEGA version 5.
HBoV Ct-values in respiratory tract samples
To study the role of HBoV Ct-values in patients with SARI, we
compared median Ct-values in three groups of patients. Groups
were deﬁned as: all hospitalized HBoV patients, all PICU-
admitted patients with HBoV and viral co-detection, and
selected PICU-admitted patients with a single HBoV infection.
Validation method using RSV infections
To validate our algorithm we applied the exact same selection
steps to RSV-positive samples of patients admitted to PICU. We
chose RSV for validation because its role in children with SARI
is well-established compared with other pathogens and we
therefore expected that RSV-related SARI admissions would
remain to be identiﬁable after using our algorithm [15–17].
Statistical analysis
Data were analysed using SPSS version 20.0 (IBM, SPSS, Chi-
cago, IL, USA) and GRAPHPAD PRISM version 6 (GraphPad, San
Diego, CA, USA). For continuous data, medians, interquartile
range (IQR), lower and upper IQR were calculated. For the
assessment of HBoV viral loads, median Ct-values were
compared using the Mann–Whitney U test. A p value <0.05 was
taken as threshold of statistical signiﬁcance.
Ethics considerations
The Medical Ethical Committee of the Erasmus MC approved
this study (MEC 2013-221). Informed consent was waived
because this is a retrospective cohort study. Data were stored
anonymously and cannot be retraced to individual patients.ResultsPatient and sample inclusion
In total 990 paediatric patients with a median age of 0.82 years
(IQR 3.13), were identiﬁed for whom respiratory viral di-
agnostics were performed. Of those, 178 patients (18%) were
HBoV RT-PCR-positive. PICU admission was necessary for 49
HBoV cases (28%), of which 20/49 were positive for HBoV
alone (41%) and 29/49 were positive for HBoV and other vi-
ruses (59%) (see Supplementary material, Table S2). Subse-
quently, clinical charts were reviewed and only patientsious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 964.e1–964.e8
CMI Moesker et al. A single human bocavirus infection can cause severe disease 964.e4admitted to PICU because of SARI were selected (11/20, 55%).
Next, samples of patients with CRP levels 40 mg/L upon
admission were included (8/11, 73%). Lastly, cases with negative
blood, liquor and sputum cultures (if available) and negative RT-
PCR test results for M. pneumoniae were selected. Sputa were
obtained from intubated children. A total of 7/8 cases (88%)
were considered with a single HBoV infection resulting in SARI
and their samples were tested with NGS (see Fig. 1).
Next-generation sequencing of HBoV cases
The seven identiﬁed respiratory tract samples were subjected
to NGS and near full-length genomes were obtained in most
samples (see Supplementary material, Table S3). No other viral
pathogens besides HBoV were detected with NGS in seven
cases selected with our algorithm (2.8–44.3% of total number
of analysed reads).
Clinical data from children with HBoV
The median age of the seven children with HBoV was 24
months (min 4.4, max 31.4, IQR 15.7–28) and four patientsFIG. 1. Flowchart for patient selection of human bocavirus RT-PCR-positive
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inwere female (4/7, 57%). One patient was 4 months old upon
admission and was born prematurely with a gestational age of
27 weeks and was previously diagnosed with bronchopulmo-
nary dysplasia. Because of the small sample size we referred
from further comparative statistical testing. The length of
symptoms before PICU admission was 1–7 days. Upon PICU
admission CRP levels with a median of 8 mg/L (min 1, max 36,
IQR 5–28) were tested within a median PICU stay of 2.5 h (min
0, max 6 h). For 6/7 children follow-up CRP levels were ob-
tained. In two children there was an increase in CRP, none of
these CRP levels were 80 mg/L (see Table 2). For patient 2,
CRP levels increased after initiation of extracorporeal mem-
brane oxygenation (from 18 to 58 mg/L, respectively). For the
other patient, negative bacterial sputum samples were obtained
in the absence of antibiotics at day 1 of the PICU stay. Three of
the seven patients (43%) with a single HBoV infection had no
pre-existing medical history. All seven patients received anti-
biotics during admission and required supplemental oxygen.
Mechanical ventilation was performed in ﬁve patients (71%) and
extracorporeal membrane oxygenation treatment was neededpatients admitted to the Erasmus MC-Sophia from 2007 to 2012.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 964.e1–964.e8
FIG. 2. Comparison between median Ct-values of human bocavirus
(HBoV) RT-PCR-positive respiratory tract samples of paediatric patient
admitted to the Erasmus MC-Sophia from 2007 to 2012; all hospital-
admitted paediatric patients versus patients admitted to the paediatric
intensive care unit (PICU) with HBoV and viral co-detection versus
PICU-admitted patients with a single HBoV infection. Horizontal bars
represent group medians.
TABLE 2. Overview non-structured follow-up C-reactive




1 1.5 2 2.5 3 3.5 4
Patient 1 5 — — — — — —
Patient 2 36 18 55 58 41 — —
Patient 3 8 — 4 — — — —
Patient 4 11 9 — 5 — — —
Patient 5 28 — 79 — 66 — 10
Patient 6 7 — 1 — — — —
Patient 7 1 — 5 — 6 — 4
— , represents missing data.
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of PICU admission was 4 days (IQR 2–7 days) (see Table 1).
Phylogenetic analysis of HBoV
To study whether a speciﬁc subtype of HBoV was associated
with severe disease, phylogenetic analyses were performed.
The VP1/VP2 region of HBoV was successfully ampliﬁed in all
seven selected cases (100%) and 40 controls (87%) (see Sup-
plementary material, Fig. S1).
BLAST and phylogenetic analyses showed that all HBoV strains
of cases and controls were closely related to a total of two
reference genotypes corresponding to HBoV genotype 1
(Stockholm: ST1 and ST2) [22].
HBoV Ct-values in respiratory tract samples
We compared the median HBoV Ct-values to study whether a
low Ct-value resulted in severe disease and if viral co-detection
resulted in higher Ct-values. We found signiﬁcantly lower Ct-
values in the seven-selected HBoV-positive cases (median Ct-
value 15.6, IQR 11.6–16.3) compared with all HBoV-positive
patients admitted to hospital (median Ct-value 33.9, IQR
11.3–36.8) (p <0.0001) (see Fig. 2).
Furthermore, HBoV Ct-values were signiﬁcantly lower
compared with 29 PICU patients with HBoV and viral co-
detection (median Ct-value 28.6, IQR 13.6–35.45) (p 0.001)
(see Fig. 2).
Validation method using RSV infections
Of the 990 paediatric patients, 366 tested positive for RSV on
RT-PCR (37%). PICU admission was required in 72/366 of RSV
cases (20%). After applying our selection steps, 17/24 RSV RT-
PCR-positive samples were tested with NGS (71%). Of these,
15/17 samples yielded results (88%). One sample could not be
processed; another had a limited number of reads. In all sam-
ples, RSV was detected (0.01–31.7% of total number of ana-
lysed reads). In addition, in one sample a rhinovirus was co-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdetected (1.17% reads; Fig. 3 and see Supplementary material,
Table S4). Overall, in 14/72 SARI PICU patients RSV was found
to be the sole pathogen (19%).DiscussionWe here present a study on the relation between a recently
discovered viral pathogen—HBoV—and SARI in children. We
analysed HBoV RT-PCR-positive samples from paediatric pa-
tients in whom viral and bacterial co-infections were consid-
ered unlikely after a rigid selection process. Pivotal to our
approach is the addition of NGS to the clinical and conven-
tional laboratory data. Based on the algorithm and NGS, we
showed that a single HBoV infection caused SARI in seven
patients requiring PICU admission. Which is in concordance
with case reports on severely ill children with HBoV infection
[7–14]. Although, in these reports viral and bacterial co-
infections were described, they were not structurally
assessed and NGS was not performed to detect overlooked
viruses [7–14].
By adding NGS to our selection method, we bypassed the
limitation of testing with RT-PCR alone, which relies on the use
of selected primers for suspected pathogens. NGS allows
detection of variant viruses that would otherwise escape
detection [23,24]. It is speciﬁcally designed to detect viruses
and is optimized to decrease the number of other nucleic acids
from host and bacteria. We showed previously that theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 964.e1–964.e8
FIG. 3. Flowchart for patient selection of respiratory syncytial virus RT-PCR-positive patients admitted to the Erasmus MC-Sophia from 2007 to 2012.
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RT-PCRs in respiratory specimens [25]. The routine clinical use
of NGS alone is still in development, but it may well be that it
will replace RT-PCR in the future [24].
In addition to the NGS ﬁndings, we also studied the differ-
ence between median HBoV Ct-values of selected cases and
other patients with HBoV detection. We found a signiﬁcantly
lower median Ct-value in the selected cases than in patients
who were also admitted to PICU, but who had viral co-
detection. This may indicate that a single recent HBoV infec-
tion is associated with a higher viral load than in combination
with other viruses, as suggested previously by other studies
[13,26,27]. Based on the age of the patients and the low Ct-
values we assume that the severe HBoV infection was a
consequence of a primary infection [13]. Furthermore, we
compared the median Ct-values of selected cases with patients
not admitted to PICU with HBoV and found that the Ct-valuesClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inof the selected cases were also signiﬁcantly lower, suggesting a
direct relation between disease severity and viral load as re-
ported by others [10,13,27]. Interestingly, others have also
found a relation between Ct-values, gender and underlying
disease. Unfortunately our sample size was too small to conﬁrm
or refute these ﬁndings [13].
In order to benchmark our algorithm that was used to
exclude patients with viral and bacterial co-infections, we also
applied it to patients with RSV infection. We only found 14
cases with RSV as the single causative agent for SARI. Consid-
ering the incidence of RSV-associated hospitalizations, this is
lower than expected [17]. We were able to benchmark our
algorithm, although it seems to be very stringent and results in
an underestimation of the true HBoV epidemiology. It is
therefore of note that we did not set out to estimate the true
burden of disease of HBoV, but to establish whether HBoV by
itself can cause SARI. Our study is subject to several limitations.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 964.e1–964.e8
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its inherent limitations may have resulted in a sample bias.
Blood samples for HBoV serology or PCR were not obtained,
because these are not routinely tested at our hospital.
Furthermore, not all bacteriology samples were obtained, as
more invasive procedures would have had to be carried out to
fully rule out the role of bacteria in lower respiratory tract
infections. These are currently not routinely practiced in crit-
ically ill children for ethical and technical reasons. As an alter-
native we set strict CRP levels to our inclusion criteria. Based
on previously published data we set a lower cut-off for bacterial
co-infections (40 mg/L) than the usually applied 80 mg/L, to
minimize the contribution of bacterial infections to the
observed disease. In addition, during non-structured follow up,
none of the patients showed an increase in CRP levels >80 mg/
L. Still, in two cases a moderate increase was observed and it
should be noted that despite these low CRP levels, bacterial
involvement cannot be fully ruled out based on CRP levels
alone [28–30]. Other biomarkers such as pro-calcitonin and
interleukins could have been used to differentiate between
bacterial and viral infections, but these were not carried out in
our hospital [30,31].
Based on our ﬁndings we conclude that a single HBoV
infection can cause SARI in children in the absence of viral and
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